Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence
Authors' conclusion
We identified that indirect adherence measurements did not reflect real-life adherence.
Study context
- Population
- Patients over 18 years with rheumatoid arthritis (RA) treated by methotrexate (MTX) for more than 6 months, Reims University Hospital26 oral MTX, 58 subcutaneous (SC) MTX
- Participants
- 84 participants
- Exposure
- Adherence to MTX by METU vs indirect adherence measures
- Outcome
- Adherence to MTX assessed with METU, compared with indirect adherence measurement technics
Methodological detailssingle-centre, real-life conditions
- Single-centre
- Real-life conditions
Main finding
As reported in the abstract
Adherence to MTX
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Adherence, MPR vs METU in SC MTX users (subgroup)Not significantly different | P = 0.059 |
Tender joint count and CRP in non-adherent vs adherent patients
- Non-adherent patients had a higher number of tender joints and CRP value
- P < 0.05
Original publication
Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence. RMD Open. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →